Benioff was on the show to talk about the company's Work.com website, which is "an all-new suite of solutions and advisory resources to help businesses and community leaders around the world to support the health and well being of their employees."
The company is now adding a vaccine component to the website. While that will include already available vaccines, such as for the flu, it's gearing up for the release of Covid-19 vaccines.
When the COVID-19 vaccine is released, there will likely be many of them. We need to leverage technology to separate the "wheat from the chaff," finding out which vaccines are the best, he said.
This will be one of the largest technological and logistical challenges in the world, Benioff said.
Many companies are going to play a role in the success of a vaccine, possibly even Snowflake (SNOW) . Salesforce is an investor in the company and Benioff explained that Salesforce continues to invest in its ecosystem where it sees opportunity.
We last looked at CRM back on August 26 and wrote that "Stay long CRM and consider raising stops to a close below $210 now from below $200. Our next price target is $285 and then the round number of $300."
Prices stopped 50 cents short of our $285 target and pulled back in September but remained well above our stop recommendation. Let's check on the charts of CRM again to see if we need to change our technical strategy.